Home
overview
The ultimate aim of the pharmaceutical industry is produce drugs that will prevent autoimmune disorders and immunodeficiencies. Such drugs would have significant market potential and implications for immune disorder sufferers. Although lack of knowledge and the complexity of these disorders have in the past led to a large number of drugs failing in development. However, as a result of better understanding of the basic mechanisms of immune disorders and increased insight into the genetic, significant therapeutic advances are in sight. Recent developments within the industry promote optimism that new and successful treatments are giving rise to an emerging market.

Immune disorders aims to explore the current key issues within the industry and the opportunities for the future of drug design. Topics covered at the conference will include autoimmune disorder therapies and the potenial value of antibody therapies.

Why should you attend this event?

This comprehensive conference is organised and produced by SMi : we specialise in providing senior executives with timely, strategic and focused up to date information. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions. The conference will of course also be an ideal opportunity for you to network with a focused and appropriate audience.

Conference programme

8:30 Registration and Coffee

9:00 Chairperson's Opening Remarks

Dr Luciano Adorini

Dr Luciano Adorini, Chief Executive Officer, BioXell

9:10 IMMUNOLGICAL MECHANISMS ASSOCIATED WITH THE DEVELOPMENT OF AUTOIMMUNE DISEASES

Mr Ronald Gladue

Mr Ronald Gladue, Senior Research Investigator, Pfizer

  • Aberent cell activation
  • Role of cell trafficking and chemokines
  • Current therapeutic options and limitations
  • 9:40 To be confirmed

    10:20 AVAILABLE AND FUTURE THERAPIES FOR MS

    Dr Luciano Adorini

    Dr Luciano Adorini, Chief Scientific Officer, BioXell

  • Selective immunointervention in autoimmune diseases
  • New perspectives in MS treatment
  • Immunoablative therapy with autologous haemopoietic stem cells support
  • Comparisons of immunomodulatory treatments in early stages of MS
  • Drugs approved for use
  • Treatments under development
  • 11:00 Morning Coffee

    11:20 NEWER APPROACHES TO TREATMENT OF INFLAMMATORY ARTHRITIS

    Dr Alan Solinger

    Dr Alan Solinger, Director, Clinical Research, Amgen

  • Interleukin 1 and its role in synovitis
  • TNF and its role in synovitis
  • Blockade of either IL-1 or TNF leads to significant improvement
  • Possibility that combination of two anticytokines therapies may be superoptimal
  • 12:00 NOVEL THERAPIES FOR AUTOIMMUNE INFLAMMTION

    Dr Timo Veromaa

    Dr Timo Veromaa, Vice President, Drug Development, BioTie Therapies

  • Dual role of VAP-1 in autoimmune inflammation
  • Target for antibody therapy as a non-classical, inflammation-inducible endothelial cell adhesion molecule recruiting activated T cells and NK cells to sites of inflammation
  • Development program of vapaliximab, a humanised anti-VAP-1 monoclonal antibody in a unique IgG2Da frame with enhancement affinity for Fc¾Rllb
  • Introducing VAP-1 SSAO (semicarbazide sensitive amine oxidase) as a target for small molecule inhibitors
  • Status of the development program of VAP-1 SSAO inhibitors for rheumatoid arthritis
  • 12:40 Lunch

    14:00 THE USE OF ORALLY-ADMINISTERED INTERFERON ALPHA IN THE MANAGEMENT OF AUTOIMMUNE DISEASE

    Dr Joseph Cummins

    Dr Joseph Cummins, President & Chief Executive Officer, Amarillo Biosciences

  • Use of oromucosal interferon in autoimmune diseases - Behcet’s disease - Sjogren’s syndrome - Keratoconjunctivitis sicca
  • Use of oromucosal interferon in diseases of unknown origin - Fibromyalgia syndrome - Idiopathic pulmonary fibrosis - Aphthous stomatitis
  • 14:40 AUTOIMMUNE DIABETES: THERAPY & PREVENTION

    Dr Dana Elias

    Dr Dana Elias, Vice President, Research & Development, PEPTOR

  • Understanding the autoimmune process in diabetes
  • Type 1 diabetes and LADA: definition of target population
  • Novel immunological approaches to prevention or treatment of diabetes
  • DiaPep277 in type 1 diabetes: clinical studies
  • Current and future studies
  • 15:20 Afternoon Tea

    15:40 TREATMENT OF IMMUNE DISORDERS

    Dr Andres Crespo

    Dr Andres Crespo, Chief Executive Officer, Genepoietic

  • Manufacturing
  • Quality control
  • Regulatory aspects
  • 16:20 ROLE OF BAFF

    Dr Susan Kalled

    Dr Susan Kalled, Senior Scientist/Project leader, Biogen

  • Introduction: BAFF and BAFF receptors
  • The link between BAFF and B cell biology
  • Implications of BAFF over expression
  • The link between BAFF and autoinmmunity
  • The effect of BAFF blockade in animal models of disease: SLE, RA, EAE
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairperson's Opening Remarks

    Dr Amanda Proudfoot

    Dr Amanda Proudfoot, Head, Protein Biochemistry, Serono

    9:10 CHEMOKINE RECEPTOR ANTAGONISTS

    Dr Richard Horuk

    Dr Richard Horuk, Director, Immunology, Berlex Biosciences

  • Chemokines and their receptors
  • Animal knockout data
  • Problems in targeting chemokine receptors
  • Summary of small molecule approaches
  • Status of clinical trials with chemokine receptor antagonists
  • 9:40 LESSONS LEARNT FROM AMINO TERMINALLY MODIFIED CHEMOKINES

    Dr Amanda Proudfoot

    Dr Amanda Proudfoot, Head, Protein Biochemistry, Serono

  • Chemokine-receptor activation
  • Chemokine receptors involved in inflammation
  • Modified chemokines as potential therapeutics
  • Which receptor(s) do we need to block?
  • Lessons learnt from administration in disease models
  • New target indentification for HIV
  • 10:20 BIOLOGICAL THERAPEUTICS IN AUTOIMMUNITY

    Dr Campbell Bunce

    Dr Campbell Bunce, Senior Scientist, Xenova

  • Current immunomodulating strategies
  • Chemokines in disease
  • Chemokine redundancy
  • Specific chemokine antagonists
  • Promiscuous chemokine antagonists
  • The future of chemokine intervention
  • 11:00 Morning Coffee

    11:20 ANTIGEN SPECIFIC APPROACH FOR TREATMENT OF IMMUNE DISORDER*

    Dr Daniel Zimmerman, Senior Vice President, Research, Cell Immunology, CEL-SCI

    Dr Daniel Zimmerman, Senior Vice President, Research, Cell Immunology, CEL-SCI, *In association with :, Dr E Taylor, CEL-SCI and Dr N Rose & Dr Y Wang, Dept of Pathology, John Hopkins School of Medicine

  • Background on autoimmune myocarditis and its role in heart failure
  • Antigen specific nature if disease and effect of L.E.A.P.S constructs
  • Alteration of cytokine profile by use of L.E.A.P.S constructs
  • Avoiding action on complement system
  • Preliminary data on mode of action
  • Potential for application in man
  • 12:00 COMING OF AGE

    Dr Xiao-Yu Song

    Dr Xiao-Yu Song, Senior Research Scientist, Immunobiology Research, Centocor

  • Nature and specificity of monoclonal antibody
  • Development paradigm for monoclonal antibody
  • Targeting key pathological pathways in chronic inflammatory disease
  • The application of anti-cytokine therapies
  • Future challenges and prospects
  • 12:40 Lunch

    14:00 TOLERANCE INDUCTION IN PRIMATES

    Dr Paul Ponath

    Dr Paul Ponath, Director, Immunology Research & Development, TolerRX

  • Tolerance induction using monoclonal antibodies
  • Durable, long term tolerance induction from a short therapeutic course of antibody
  • The role of regulatory T cells in the induction and maintenance of tolerance by monoclonal antibodies
  • 14:40 TARGETING CD45RB WITH HUMAN ANTIBODIES

    Dr Geoffrey Davis

    Dr Geoffrey Davis, Chief Scientific Officer, Abgenix

  • Mechanistic studies with anti-CD45RB antibodies
  • Murine anti-CD45RB in mouse models of lupus and diabetes
  • Murine and chimeric anti-CD45RB in rhesus renal transplant models
  • Development of a fully human antibody using XenomaxTM technology
  • 15:20 Afternoon Tea

    15:40 THERAPEUTIC PHARMACCINES

    Dr Anand Gautam

    Dr Anand Gautam, Senior Vice President, Pharmexa

  • AutoVacTM approach targeting pathogenic self proteins in chronic diseases
  • Breaking immune tolerance against target proteins (eg TNFa) by AutoVacTM
  • AutoVacTM, a genetic modification of self antigens by foreign T helper peptides
  • Models of Inflammation, bone loss, asthma and cancer and AutoVacTM
  • Current clinical trials and vaccines in development
  • Advantages of AutoVac: Active versus passive immunotherapy
  • 16:20 MALIGNANCY

    Dr Christopher Nicodemus

    Dr Christopher Nicodemus, Senior Vice President, Clinical Research & Development, Altarex

  • Evidence for immunodeficiency in malignancy
  • Allogeneic transplatation and protective immunity in leukemia
  • HIV and malignant syndromes
  • Strategies to mobilize tumorcidal immunity
  • Immune processing of autologous tumour antigen
  • Therapeutic potential of xenotypic antibodies, clinical experience and future directions
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.